|
Baseline therapy
|
Add-on Therapy
|
Size¶
|
Drop out§
|
Mean 6MWD improvement
|
Mean age
|
Prop male
|
Mean STATUS
|
Mean 6MWD baseline
|
Mean PVR
|
|---|
|
ERA + PDE5i
|
Placebo*
|
23
|
4
|
2.54 (16.25)
|
50.30
|
0.30
|
2.96
|
342.07
|
1157.0
|
|
ERA + PDE5i
|
Imatinib
|
20
|
12
|
43.7 (14.27)
|
50.15
|
0.10
|
2.60
|
328.95
|
1282.1
|
|
ERA + Pr
|
Placebo
|
8
|
2
|
7.81 (14.36)
|
37.00
|
0.25
|
2.38
|
381.56
|
1146.6
|
|
ERA + Pr
|
Imatinib
|
10
|
5
|
48.3 (16.12)
|
47.20
|
0.00
|
2.80
|
331.60
|
1071.9
|
|
ERA + PDE5i + Pr
|
Placebo
|
33
|
8
|
−8.27 (10.47)
|
47.03
|
0.18
|
2.73
|
355.79
|
1176.6
|
|
ERA + PDE5i + Pr
|
Imatinib
|
27
|
15
|
33.37 (11.54)
|
47.74
|
0.19
|
2.85
|
360.70
|
1232.5
|
|
PDE5i + Pr
|
Placebo
|
16
|
4
|
36.03 (10.53)
|
43.19
|
0.06
|
2.56
|
358.72
|
1193.9
|
|
PDE5i + Pr
|
Imatinib
|
9
|
5
|
40 (14.59)
|
53.00
|
0.11
|
2.78
|
380.56
|
1050.8
|
- *ERA is any endothelin receptor antagonist, PDE5i is phosphodiesterase 5 inhibitor, and Pr is prostacyclins (oral, inhaled, intravenous or subcutaneous).
- ¶ Group size was number of patients taking 6MWD test at baseline and 24 weeks.
- § Dropout is number of patients dropping out of the study between baseline and 24 weeks. Dropout due to death, adverse events, consent withdrawal, protocol deviation, abnormal laboratory result, administrative error, or adverse reaction to study drug.
